| Naushad Banani, Dpm, Inc. | |
|
5900 South Lake Forest Drive, Suite 300 Pmb 2010, Mckinney, TX 75070-2238 | |
| (469) 443-4241 | |
| (833) 471-5540 |
| Full Name | Naushad Banani, Dpm, Inc. |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 5900 South Lake Forest Drive, Mckinney, Texas |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649994641 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | (* (Not Available)) | Primary |
| Provider Name | Naushad Pyarali Banani |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1134488877 PECOS PAC ID: 0648575712 Enrollment ID: I20230411001446 |
News Archive
Genta Incorporated announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company's novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel - a late Phase 2 oncology product - is the leading oral taxane currently in clinical development.
All newborn babies in South Australia are to get access to comprehensive hearing testing in the first few weeks of their lives.
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).
Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS - dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world's leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).
The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Naushad Banani, Dpm, Inc. 5900 South Lake Forest Drive Suite 300 Pmb 2010, Mckinney, TX 75070-2238 Ph: (469) 443-4241 | Naushad Banani, Dpm, Inc. 5900 South Lake Forest Drive, Suite 300 Pmb 2010, Mckinney, TX 75070-2238 Ph: (469) 443-4241 |
News Archive
Genta Incorporated announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company's novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel - a late Phase 2 oncology product - is the leading oral taxane currently in clinical development.
All newborn babies in South Australia are to get access to comprehensive hearing testing in the first few weeks of their lives.
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).
Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS - dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world's leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).
The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.
› Verified 1 days ago
Kinex Podiatry Pllc Podiatrist Medicare: Medicare Enrolled Practice Location: 1740 W Virginia St Ste 100, Mckinney, TX 75069 Phone: 972-709-7556 Fax: 972-709-7611 | |
Dr. Naushad Pyarali Banani, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 5900 South Lake Forest Drive, Suite 300 Pmb 2010, Mckinney, TX 75070 Phone: 469-443-4241 Fax: 833-471-5540 | |
Faiza Khan, D.P.M Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1740 W Virginia St Ste 100, Mckinney, TX 75069 Phone: 972-709-7556 Fax: 972-709-7611 | |
Stonebridge Foot & Ankle, P.l.l.c. Podiatrist Medicare: Medicare Enrolled Practice Location: 175 Ridge Rd, Ste. 800, Mckinney, TX 75070 Phone: 972-540-0006 Fax: 972-984-1102 | |
Dr. Christopher Scott Witt, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 5531 Virginia Pkwy Ste 100, Mckinney, TX 75071 Phone: 972-542-2155 | |
Podiatry Usa Corporation Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2300 Sherbrooke Ln, Mckinney, TX 75070 Phone: 972-984-0818 | |
Sunil Kumar Jeganathan, MD, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 5337 W University Dr Ste 100, Mckinney, TX 75071 Phone: 972-542-3668 Fax: 972-542-1728 |